文献速递妇科

评估AEGEA蒸汽子宫内膜消融系统安全性和有效性的前瞻性多中心关键试验

A Prospective, Multicenter, Pivotal Trial to Evaluate the Safety and Effectiveness of the AEGEA Vapor Endometrial Ablation System.
PubMed 文献 · J Minim Invasive Gynecol · 2018-07-21

这项前瞻性、多中心、单臂、开放标签临床试验在155名30至50岁月经过多女性中评估AEGEA蒸汽系统。治疗12个月后,78.7%的受试者达到主要疗效终点,超过客观性能标准(p=0.0004),90.8%的受试者满意或非常满意,未报告严重不良器械效应或与操作相关的严重不良事件。

要点

  • 治疗12个月后78.7%的受试者达到主要疗效终点,超过客观性能标准(p=0.0004)。
  • 90.8%的受试者满意或非常满意,99%的受试者生活质量评分改善。
  • 未报告严重不良器械效应或与操作相关的严重不良事件。

核心结论

  • AEGEA蒸汽系统是一种安全、有效、微创的选择,可在最小麻醉下进行诊室子宫内膜消融,用于治疗月经过多女性。

研究设计与样本

  • 前瞻性、多中心、单臂、开放标签临床试验,在美国、加拿大、墨西哥和荷兰的15个研究中心开展。
  • 共纳入155名30至50岁、经 pictoria 失血量评估评分≥150确认为月经过多的绝经前女性。
  • 随访评估在子宫内膜消融术后24小时、2周、3个月、6个月和12个月进行(加拿大工作组分类II-1)。

主要发现

  • 治疗12个月时,78.7%的受试者达到主要疗效终点(pictoria 失血量评估评分≤75),超过客观性能标准(p=0.0004)。
  • 90.8%的受试者对治疗满意或非常满意,99%的受试者生活质量评分改善,月经影响问卷评分平均下降8.1。
  • 72%的受试者痛经减轻,85%的性生活受月经影响的女性报告性生活改善。
  • 未报告严重不良器械效应或与操作相关的严重不良事件。

关键数值与推荐

  • 主要疗效终点为月经失血量减少至 pictoria 失血量评估评分≤75。
  • 成功判定基于美国食品药品监督管理局的客观性能标准,该标准源自首批5项全球子宫内膜消融关键临床试验的成功率。
  • 次要疗效终点包括月经影响问卷和阿伯丁月经过多严重度评分评估的生活质量和患者满意度,以及治疗后12个月内因异常出血需手术或药物干预的需求。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: To evaluate the safety and effectiveness of the AEGEA Vapor System (Aegea Medical System, Menlo Park, CA) for the treatment of heavy menstrual bleeding (HMB). DESIGN: A prospective, multicenter, single-arm, open-label, clinical trial. Follow-up assessments were conducted at 24 hours; 2 weeks; and 3, 6, and 12 months after the endometrial ablation procedure (Canadian Task Force Classification II-1). SETTING: A private practice and outpatient and hospital settings at 15 sites in the United States, Canada, Mexico, and the Netherlands. PATIENTS: One hundred fifty-five premenopausal women aged 30 to 50years with HMB as determined by a pictorial blood loss assessment score ≥150. Preoperative evaluation included ultrasound, sonohysterography or hysteroscopy, and endometrial biopsy. Screening inclusion allowed treatment of up to 12-cm uterine sound lengths and nonobstructing myomata. INTERVENTIONS: Endometrial ablation (120-second treatment time) was performed under varying anesthesia regimens using the vapor system from September 2014 to May 2015. MEASUREMENTS AND MAIN RESULTS: The primary effectiveness end point was the reduction of menstrual blood loss to a pictorial blood loss assessment score ≤75. Success was judged based on the Food and Drug Administration's objective performance criteria, derived from the success rates of the first 5 global endometrial ablation pivotal clinical trials. The secondary effectiveness end points included quality of life and patient satisfaction as assessed using the Menorrhagia Impact Questionnaire and the Aberdeen Menorrhagia Severity Score as well as the need for surgical or medical intervention to treat abnormal bleeding at any time within the first 12 months after treatment. All adverse events, including device- and procedure-related events, were recorded. At 12 months, the primary effectiveness end point was achieved in 78.7% of subjects exceeding the OPC (p = .0004); 90.8% of subjects were satisfied or very satisfied with the treatment. Ninety-nine percent of subjects showed improvement in quality of life scores with an average decrease in the Menorrhagia Impact Questionnaire score by 8.1, 72% had less dysmenorrhea, and 85% of women whose sex lives were affected by their menses reported improvement in their sex lives. There were no reported serious adverse device effects or any reported serious adverse events that were procedure related. CONCLUSION: The AEGEA Vapor System is a safe, effective, and minimally invasive option for performing in-office endometrial ablation under minimal anesthesia for the purpose of treating women who suffer from HMB.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Levie MD, Chudnoff SG. A Prospective, Multicenter, Pivotal Trial to Evaluate the Safety and Effectiveness of the AEGEA Vapor Endometrial Ablation System. J Minim Invasive Gynecol. 2018. PMID: 30036631. doi:10.1016/j.jmig.2018.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。